Replies to post #84495 on Biotech Values

[genisi]

And there's the litigation with Baxter regarding methods of screening the samples. Kamada is too small and its capacity isn't a real threat to Talecris unless of course the inhaled AAT gets approved.

[DewDiligence]

IGIV is Talecris's biggest product.

Gamunex/IGIV comprised 61% of TLCR’s total sales in 3Q09. TLCR is essentially a two-product company: Gamunex and Prolastin.

[DewDiligence]

Does anyone think this IGIV survey was unbiased?

http://finance.yahoo.com/news/GamunexR-is-the-Preferred-prnews-1535189131.html?x=0&.v=1

In the survey, conducted online by Harris Interactive on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

LOL re the p-value.